Dianthus Therapeutics Inc (NAS:DNTH)

$ 22.55 0.81 (3.73%) Market Cap: 661.83 Mil Enterprise Value: 261.52 Mil PE Ratio: 0 PB Ratio: 1.71 GF Score: 20/100

Dianthus Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call Transcript
May 03, 2023
Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call Transcript
Dec 13, 2022
Magenta Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2022
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call Transcript
May 12, 2021
Magenta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Magenta Therapeutics, Inc. - Special Call Transcript
May 07, 2020
Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Magenta Therapeutics Inc ASH 2019 Transcript
Dec 08, 2019
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 11, 2019

Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call Transcript

May 12, 2021 / 08:30PM GMT

Transcript 10-Q8-K

Operator

Good day, and thank you for standing by. Welcome to the Magenta Therapeutics Conference Call. (Operator Instructions)

I would now like to hand the conference over to your first speaker today, Jim Haney, Senior Director, Investor Relations. Thank you. Please go ahead.

Jim Haney

Magenta Therapeutics, Inc. - Senior Director of IR

Thank you, Paul, and good afternoon, everyone. Thank you for joining us today for a review of the preliminary data from the MGTA-145 in combination with plerixafor Phase II study in patients with multiple myeloma, disclosed in the abstract posted this morning for the European Hematology Association Congress to be held in June. We issued a press release earlier this morning on the preliminary data, and that press release can be found on the Investors and Media section of our website.

With me on the call today are Dr. Jason Gardner, Magenta Therapeutics President, CEO and Co-Founder; Dr. John Davis, Chief Medical Officer and Head of Research and Development; Steve Mahoney, Chief Financial and Operating Officer; Dr. David

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.